Developing science,
delivering therapies


Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more


A landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson’s disease and accelerate the development of new treatments 4D pharma will play an important role as PPMI considers the microbiome as an area of focus
Merger completion and NASDAQ listing expected in Q1 2021. US listing will support and accelerate ongoing development of 4D pharma’s Live Biotherapeutics.
MRx0518 demonstrates upregulation of key immune biomarkers associated with anti-cancer activity in neoadjuvant monotherapy setting; Addition of new tumor type cohorts to ongoing Part B of Phase I/II combination trial with pembrolizumab, following 42% disease control rate (DCR) in completed Part A; Company to host virtual KOL event to review data on Wednesday, November 11, 2020 at 1:00pm GMT (8:00am ET)